Chemotherapy is the most common treatment strategy for cancer patients. Nevertheless, limited drug delivery to cancer cells, intolerable toxicity, and multiple drug resistance are constant challenges of chemotherapy. Novel targeted drug delivery strategies by using nanoparticles have attracted much attention due to reducing side effects and increasing drug efficacy. Therefore, the most important outcome of this study is to answer the question of whether active targeted HA-based drug nanocarriers have a significant effect on improving drug delivery to cancer cells.
This study aimed to systematically review studies on the use of hyaluronic acid (HA)-based nanocarriers for chemotherapy drugs. The two databases MagIran and SID from Persian databases as well as international databases PubMed, WoS, Scopus, Science Direct, Embase, as well as Google Scholar were searched for human studies and cell lines and/or xenograft mice published without time limit until 2020. Keywords used to search included Nanoparticle, chemotherapy, HA, Hyaluronic acid, traditional medicine, natural medicine, chemotherapeutic drugs, natural compound, cancer treatment, and cancer. The quality of the studies was assessed by the STROBE checklist. Finally, studies consistent with inclusion criteria and with medium- to high-quality were included in the systematic review.
According to the findings of studies, active targeted HA-based drug nanocarriers showed a significant effect on improving drug delivery to cancer cells. Also, the use of lipid nanoparticles with a suitable coating of HA have been introduced as biocompatible drug carriers with high potential for targeted drug delivery to the target tissue without affecting other tissues and reducing side effects. Enhanced drug delivery, increased therapeutic efficacy, increased cytotoxicity and significant inhibition of tumor growth, as well as high potential for targeted chemotherapy are also reported to be benefits of using HA-based nanocarriers for tumors with increased expression of CD44 receptor.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Datasets are available through the corresponding author upon reasonable request.
Scientific Information Database
Medical Subject Headings
Web of Science
Preferred Reporting Items for Systematic Reviews and Meta-Analysis
Wang H, Naghavi M, Allen C, Barber RM, Bhutta ZA, Carter A, et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. The lancet. 2016;388(10053):1459–544.
Zheng PP, Li J, Kros JM. Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights. Med Res Rev. 2018;38(1):325–76.
Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries (vol 68, pg 394, 2018). CA-A Cancer J Clin. 2020;70(4):313.
Blagosklonny MV. Target for cancer therapy: proliferating cells or stem cells. Leukemia. 2006;20(3):385–91.
Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer. 2017;17(2):93.
Visconti R, Della Monica R, Grieco D. Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword. J Exp Clin Cancer Res. 2016;35(1):1–8.
Gillet J-P, Gottesman MM. Mechanisms of multidrug resistance in cancer. Multi-drug resistance in cancer. Methods Mol Biol. 2010;596:47–76.
Schirrmacher V. From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment. Int J Oncol. 2019;54(2):407–19.
Strebhardt K, Ullrich A. Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008;8(6):473–80.
Zhuang Y, Deng H, Su Y, He L, Wang R, Tong G, et al. Aptamer-functionalized and backbone redox-responsive hyperbranched polymer for targeted drug delivery in cancer therapy. Biomacromol. 2016;17(6):2050–62.
Wu G, Wang Z, Bian X, Du X, Wei C. Folate-modified doxorubicin-loaded nanoparticles for tumor-targeted therapy. Pharm Biol. 2014;52(8):978–82.
Qi X, Fan Y, He H, Wu Z. Hyaluronic acid-grafted polyamidoamine dendrimers enable long circulation and active tumor targeting simultaneously. Carbohyd Polym. 2015;126:231–9.
Yang B, Ni X, Chen L, Zhang H, Ren P, Feng Y, et al. Honokiol-loaded polymeric nanoparticles: an active targeting drug delivery system for the treatment of nasopharyngeal carcinoma. Drug Delivery. 2017;24(1):660–9.
Bae Y, Kataoka K. Intelligent polymeric micelles from functional poly (ethylene glycol)-poly (amino acid) block copolymers. Adv Drug Deliv Rev. 2009;61(10):768–84.
Mashayekhi S, Rasoulpoor S, Shabani S, Esmaeilizadeh N, Serati-Nouri H, Sheervalilou R, et al. Curcumin-loaded mesoporous silica nanoparticles/nanofiber composites for supporting long-term proliferation and stemness preservation of adipose-derived stem cells. Int J Pharm. 2020;587:119656.
Chen W, Zhong P, Meng F, Cheng R, Deng C, Feijen J, et al. Redox and pH-responsive degradable micelles for dually activated intracellular anticancer drug release. J Control Release. 2013;169(3):171–9.
Kapoor A, Kumar S. Cancer stem cell: A rogue responsible for tumor development and metastasis. Indian J Cancer. 2014;51(3):282.
Sanità G, Carrese B, Lamberti A. Nanoparticle Surface Functionalization: How to Improve Biocompatibility and Cellular Internalization. Front Mol Biosci. 2020;7:587012.
Cho H-J, Yoon I-S, Yoon HY, Koo H, Jin Y-J, Ko S-H, et al. Polyethylene glycol-conjugated hyaluronic acid-ceramide self-assembled nanoparticles for targeted delivery of doxorubicin. Biomaterials. 2012;33(4):1190–200.
Zhong Y, Zhang J, Cheng R, Deng C, Meng F, Xie F, et al. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts. J Control Release. 2015;205:144–54.
Yin S, Huai J, Chen X, Yang Y, Zhang X, Gan Y, et al. Intracellular delivery and antitumor effects of a redox-responsive polymeric paclitaxel conjugate based on hyaluronic acid. Acta Biomater. 2015;26:274–85.
Xiong H, Du S, Ni J, Zhou J, Yao J. Mitochondria and nuclei dual-targeted heterogeneous hydroxyapatite nanoparticles for enhancing therapeutic efficacy of doxorubicin. Biomaterials. 2016;94:70–83.
Sun B, Deng C, Meng F, Zhang J, Zhong Z. Robust, active tumor-targeting and fast bioresponsive anticancer nanotherapeutics based on natural endogenous materials. Acta Biomater. 2016;45:223–33.
Teng C, Chai Z, Yuan Z, Ren L, Lin C, Yan Z, et al. Desirable pegylation for improving tumor selectivity of hyaluronic acid-based nanoparticles via low hepatic captured, long circulation times and cd44 receptor-mediated tumor targeting. Nanomed Nanotechnol Biol Med. 2020;24:102105.
Freag MS, Elnaggar YS, Abdelmonsif DA, Abdallah OY. Layer-by-layer-coated lyotropic liquid crystalline nanoparticles for active tumor targeting of rapamycin. Nanomedicine. 2016;11(22):2975–96.
Kesharwani P, Banerjee S, Padhye S, Sarkar FH, Iyer AK. Hyaluronic acid engineered nanomicelles loaded with 3, 4-difluorobenzylidene curcumin for targeted killing of CD44+ stem-like pancreatic cancer cells. Biomacromol. 2015;16(9):3042–53.
Suh MS, Shen J, Kuhn LT, Burgess DJ. Layer-by-layer nanoparticle platform for cancer active targeting. Int J Pharm. 2017;517(1–2):58–66.
Lu B, Xiao F, Wang Z, Wang B, Pan Z, Zhao W, et al. Redox-sensitive Hyaluronic Acid Polymer Prodrug Nanoparticles for Enhancing Intracellular Drug Self-Delivery and Targeted Cancer Therapy. ACS Biomater Sci Eng. 2020.
Mizrahy S, Goldsmith M, Leviatan-Ben-Arye S, Kisin-Finfer E, Redy O, Srinivasan S, et al. Tumor targeting profiling of hyaluronan-coated lipid based-nanoparticles. Nanoscale. 2014;6(7):3742–52.
Li J, Li M, Tian L, Qiu Y, Yu Q, Wang X, et al. Facile strategy by hyaluronic acid functional carbon dot-doxorubicin nanoparticles for CD44 targeted drug delivery and enhanced breast cancer therapy. Int J Pharmac. 2020;578:119122.
Upadhyay KK, Mishra AK, Chuttani K, Kaul A, Schatz C, Le Meins J-F, et al. The in vivo behavior and antitumor activity of doxorubicin-loaded poly (γ-benzyl l-glutamate)-block-hyaluronan polymersomes in Ehrlich ascites tumor-bearing BalB/c mice. Nanomedicine: Nanotechnol Biol Med. 2012;8(1):71–80.
Lu B, Xiao F, Wang Z, Wang B, Pan Z, Zhao W, et al. Redox-Sensitive Hyaluronic Acid Polymer Prodrug Nanoparticles for Enhancing Intracellular Drug Self-Delivery and Targeted Cancer Therapy. ACS Biomater Sci Eng. 2020;6(7):4106–15.
Arpicco S, Milla P, Stella B, Dosio F. Hyaluronic acid conjugates as vectors for the active targeting of drugs, genes and nanocomposites in cancer treatment. Molecules. 2014;19(3):3193–230.
Mattheolabakis G, Milane L, Singh A, Amiji MM. Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine. J Drug Target. 2015;23(7–8):605–18.
Dosio F, Arpicco S, Stella B, Fattal E. Hyaluronic acid for anticancer drug and nucleic acid delivery. Adv Drug Deliv Rev. 2016;97:204–36.
Sun C-Y, Zhang B-B, Zhou J-Y. Light-activated drug release from a hyaluronic acid targeted nanoconjugate for cancer therapy. Journal of Materials Chemistry B. 2019;7(31):4843–53.
Wu P, Sun Y, Dong W, Zhou H, Guo S, Zhang L, et al. Enhanced anti-tumor efficacy of hyaluronic acid modified nanocomposites combined with sonochemotherapy against subcutaneous and metastatic breast tumors. Nanoscale. 2019;11(24):11470–83.
Bazak R, Houri M, El Achy S, Kamel S, Refaat T. Cancer active targeting by nanoparticles: a comprehensive review of literature. J Cancer Res Clin Oncol. 2015;141(5):769–84.
Liu L, Liu Y, Li J, Du G, Chen J. Microbial production of hyaluronic acid: current state, challenges, and perspectives. Microb Cell Fact. 2011;10(1):1–9.
Pedrosa SS, Gama M. Hyaluronic acid and its application in nanomedicine. Carbohydrates Appl Med. 2014:55–89.
Misra S, Hascall VC, Atanelishvili I, Moreno Rodriguez R, Markwald RR, Ghatak S. Utilization of glycosaminoglycans/proteoglycans as carriers for targeted therapy delivery. Int J Cell Biol. 2015;2015:537560.
Huang G, Huang H. Application of hyaluronic acid as carriers in drug delivery. Drug Deliv. 2018;25(1):766–72.
Goodison S, Urquidi V, Tarin D. CD44 cell adhesion molecules. Molecular pathology : MP. 1999;52(4):189–96.
Kaya G, Rodriguez I, Jorcano JL, Vassalli P, Stamenkovic I. Selective suppression of CD44 in keratinocytes of mice bearing an antisense CD44 transgene driven by a tissue-specific promoter disrupts hyaluronate metabolism in the skin and impairs keratinocyte proliferation. Genes Dev. 1997;11(8):996–1007.
Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y. CD44 in cancer. Crit Rev Clin Lab Sci. 2002;39(6):527–79.
Kim JH, Moon MJ, Kim DY, Heo SH, Jeong YY. Hyaluronic acid-based nanomaterials for cancer therapy. Polymers. 2018;10(10):1133.
Wan L, Jiao J, Cui Y, Guo J, Han N, Di D, et al. Hyaluronic acid modified mesoporous carbon nanoparticles for targeted drug delivery to CD44-overexpressing cancer cells. Nanotechnology. 2016;27(13):135102.
Nie W, Zhang B, Yan X, Su L, Wang Sh, Han G, Han D. Degraded Hyaluronic Acid-Modified Magnetic Nanoparticles. J Nanomater. 2020;2020:1–8.
Yang Y, Yang Y, Xie X, Xu X, Xia X, Wang H, et al. Dual stimulus of hyperthermia and intracellular redox environment triggered release of siRNA for tumor-specific therapy. Int J Pharm. 2016;506(1–2):158–73.
Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P), , et al. elaboration and explanation. BMJ. 2015;2015:349.
Oommen OP, Garousi J, Sloff M, Varghese OP. Tailored doxorubicin-H yaluronan conjugate as a potent anticancer glyco-D rug: an alternative to prodrug approach. Macromol Biosci. 2014;14(3):327–33.
Liu Q, Li J, Pu G, Zhang F, Liu H, Zhang Y. Co-delivery of baicalein and doxorubicin by hyaluronic acid decorated nanostructured lipid carriers for breast cancer therapy. Drug Delivery. 2016;23(4):1364–8.
Zhang B, Zhang Y, Yu D. Lung cancer gene therapy: Transferrin and hyaluronic acid dual ligand-decorated novel lipid carriers for targeted gene delivery. Oncol Rep. 2017;37(2):937–44.
by the Student Research Committee of Kermanshah University of Medical Sciences.
Ethics approval and consent to participate
Consent for publication
The authors declare that they have no conflict of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Salari, N., Mansouri, K., Valipour, E. et al. Hyaluronic acid-based drug nanocarriers as a novel drug delivery system for cancer chemotherapy: A systematic review. DARU J Pharm Sci (2021). https://doi.org/10.1007/s40199-021-00416-6
- Systematic review
- CD44 receptor
- Hyaluronic acid